| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_43a72884e25aaecffebe0942132d704f
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_37f4922dfb7777b019e504b885211b8e
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_373a9b7fb8f054922fc382f5f189aad8
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_015b06914223e1628bc6a0b3d09dcde5 |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q2600-112
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q2600-106
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q2600-158 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q1-6883 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12Q1-68 |
| filingDate |
2017-09-07-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_083ee6babc3f3bd5e5ab731cdc0a589b
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_693c5a9615f272d457622e895ded1393
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_f189e43f1109be443055d786ca49888e
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_fd79363679b618a006b5b4929e1eadcf |
| publicationDate |
2018-03-15-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
WO-2018046615-A1 |
| titleOfInvention |
Methods and compositions for predicting chronic lung allograft dysfunction |
| abstract |
Inventors have used a large-scale gene expression profiling of whole blood to identify early biomarkers of CLAD. Microarray experiments performed from 80 patients identify 47 genes differentially expressed between the stable and the BOS groups. An independent set of patients was then used for an external validation by QPCR. POU Class 2 Associating Factor 1 (POU2AF1) and B-cell lymphocyte kinase (BLK) genes were confirmed as predictive markers of BOS more than 6 months before the clinical diagnosis. Accordingly, the present invention relates to a method for predicting the risk of having the CLAD in a subject comprising the following steps: i) measuring the expression level of POU2AF1 or BLK in a biological sample obtained from said subject; ii) comparing the expression level of POU2AF1 or BLK with a predetermined reference value and iii) concluding that the subject is at risk of having CLAD when the expression level of POU2AF1 or BLK is lower than the predetermined reference value. |
| isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-113234830-A
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-113234830-B
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/EP-4177608-A1 |
| priorityDate |
2016-09-08-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |